Current Cancer Drug Targets
Volume 21, 11 Issues, 2021
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research
Contents
Current Cancer Drug Targets, Volume 18 - Number 8
Biography Open Access
Review Article
The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies
, 18(8): 720 - 736Avineesh Singh, Preeti Patel, Jageshwar, Vijay Kumar Patel, Deepak Kumar Jain, M. Kamal and Harish Rajak*
DOI: 10.2174/1568009617666170630124643
The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies
Review Article
Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
, 18(8): 737 - 748Leila Farahmand, Parnaz Merikhian, Neda Jalili, Behrad Darvishi and Keivan Majidzadeh-A*
DOI: 10.2174/1568009617666170623113520
Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Review Article
p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
, 18(8): 749 - 772Surendra Kumar Nayak*, Gopal L. Khatik, Rakesh Narang, Vikramdeep Monga and Harish Kumar Chopra
DOI: 10.2174/1568009617666170623111953
p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
Review Article
Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
, 18(8): 773 - 791Dhaval Sanchala, Lokesh K. Bhatt* and Kedar S. Prabhavalkar
DOI: 10.2174/1568009617666170623123848
Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
Review Article
Development of Drug Targeting and Delivery in Cervical Cancer
, 18(8): 792 - 806Urvashi Aggarwal, Amit Kumar Goyal and Goutam Rath*
DOI: 10.2174/1568009617666171009165105
Development of Drug Targeting and Delivery in Cervical Cancer
Research Article
A High-throughput Quantitative Expression Analysis of Cancer-related Genes in Human HepG2 Cells in Response to Limonene, a Potential Anticancer Agent
, 18(8): 807 - 815Rand R. Hafidh*, Saba Z. Hussein, Mohammed Q. MalAllah, Ahmed S. Abdulamir and Fatimah Abu Bakar
DOI: 10.2174/1568009617666171114144236
A High-throughput Quantitative Expression Analysis of Cancer-related Genes in Human HepG2 Cells in Response to Limonene, a Potential Anticancer Agent
Research Article
JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells
, 18(8): 816 - 828Ilaria Zanellato*, Donato Colangelo and Domenico Osella
DOI: 10.2174/1568009617666170623101722
JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
COPE Compliant
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 5.2
Webmaster Contact: info@benthamscience.net